Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Schedule of Consolidated Assets and Non-Recourse Liabilities (Details)

v3.3.1.900
Acquisitions, Investments, and Licenses - Schedule of Consolidated Assets and Non-Recourse Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Current assets:        
Cash and cash equivalents $ 193,598 [1] $ 96,907 [1] $ 185,798 $ 27,361
Accounts receivable, net [1] 193,875 19,969    
Inventory, net [1] 39,681 16,604    
Prepaid expenses and other current assets [1] 26,904 9,389    
Total current assets [1] 454,058 142,869    
Property, plant and equipment, net [1] 131,798 16,411    
Intangible assets, net [1] 638,152 62,649    
Goodwill 743,348 [1] 224,292 [1] $ 226,373  
Other assets [1] 5,267 5,838    
Total assets [1] 2,799,614 1,267,664    
Current liabilities:        
Accounts payable [1] 72,535 8,744    
Accrued expenses [1] 167,899 60,912    
Total current liabilities [1] 251,902 83,111    
Other long-term liabilities [1] 292,470 50,205    
Total liabilities [1] $ 819,820 431,923    
SciVac | Variable Interest Entity, Primary Beneficiary        
Current assets:        
Cash and cash equivalents   393    
Accounts receivable, net   316    
Inventory, net   1,649    
Prepaid expenses and other current assets   718    
Total current assets   3,076    
Property, plant and equipment, net   1,725    
Intangible assets, net   875    
Goodwill   1,553    
Other assets   384    
Total assets   7,613    
Current liabilities:        
Accounts payable   445    
Accrued expenses   4,446    
Notes payable   5,189    
Total current liabilities   10,080    
Other long-term liabilities   2,042    
Total liabilities   $ 12,122    
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.